ABBVAbbVie

We note your disclosure regarding the company's stock repurchase programs on page 76 of the Form 10-K and your use of non-GAAP measures in your financial goals for the 2019 fiscal year, as disclosed in your Schedule 14A filed March 23, 2020. Please tell us the impact of stock repurchases, if any, on levels of executive compensation and confirm that you will discuss the impact in future filings.

The Company acknowledges the

Staff’s comment and advises the Staff that the Company’s stock repurchases had no impact on levels of executive compensation for the year ended December 31, 2019 (the “2019 Fiscal Year”). For the 2019 Fiscal Year, the Company’s stock repurchases resulted in an increase to earnings per share (“EPS”) of $0.03.

Rest of the answer

EPS is used as a metric to determine the number of performance shares granted to the Company’s senior executives, and its impact is subject to a range.

EPS exceeded the maximum range for the 2019 Fiscal Year and would still have done so if the Company had disregarded the favorable

$0.03 impact. Once the maximum is achieved, no additional performance shares are granted. Therefore, the stock repurchases did not impact the number of performance shares granted.

The Company confirms that, to the extent material to its executive compensation disclosure, it will discuss the impact of stock repurchases on levels of executive compensation in future filings.

Read in the reply ↗

We note that your incentive compensation programs use non-GAAP measures including non-GAAP income before taxes, adjusted diluted earnings per share, non-GAAP operating margins and return on assets. Additionally, we note that Appendix B does not include a reconciliation on non-GAAP Income before taxes and other reconciliations include the line item "Adjusted for specific items" without identifying the items or the

Rest of the question

specific amounts. Please explain the basis for your omission of this information and confirm you will provide it in future filings.

The Company acknowledges the

Staff’s comment and confirms that in future filings it will include a reconciliation of non-GAAP Income before taxes and identify the items or specific amounts of the line item “Adjusted for specific items.” Read in the reply ↗

We note that the forum selection provision included in Article X of your Amended and Restated Certificate of Incorporation identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any "any derivative action or proceeding brought on behalf of the Corporation." Please disclose whether this provision applies to actions arising under the Securities Act or

Rest of the question

Exchange Act. In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. If the provision applies to Securities Act claims, please also revise your disclosure to state that there is uncertainty as to whether a court would enforce such provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If this provision does not apply to actions arising under the Securities Act or Exchange Act, please also ensure that the exclusive forum provision in the governing documents states this clearly, or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Securities Act or Exchange Act.

The Company acknowledges the

Staff’s comment and advises the Staff that it will disclose that there is uncertainty whether a court would enforce the exclusive forum provision with respect to claims under federal securities laws in the Description of the Registrant’s Securities Registered

Pursuant to Section 12 of the Securities Exchange Act of 1934, which will be filed as an exhibit to the Company’s Form 10-K for the fiscal year ended December 31, 2020.

We hope that the foregoing has been responsive to the Staff’s comments.

Rest of the answer

If you have any questions related to this letter, please contact Jennifer Lagunas at 847-935-0056 or jennifer.lagunas@abbvie.com.

Read in the reply ↗

We note your response to our prior comment 3. In addition, please also revise your disclosure in future filings to clearly state whether the forum selection provision applies to actions arising under the Securities Act or Exchange Act.

The Company acknowledges the Staff’s comment and advises the Staff that it will revise its disclosure in future filings to clearly state whether the forum selection provision applies to actions arising under the Securities Act or Exchange Act.

Securities and Exchange Commission

March 19, 2021

We hope that the foregoing has been responsive to the Staff’s comments. If you have any questions related to this letter, please contact Jennifer Lagunas at 847-935-0056 or jennifer.lagunas@abbvie.com. Read in the reply ↗